HOME >> MEDICINE >> NEWS
FDA approves Dey, L.P.'s Perforomist inhalation solution for maintenance treatment of COPD

Napa, CA (May 11, 2007) Dey, L.P. announced today that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Formoterol is a rapid and long-lasting beta2 agonist that has been previously approved in the U.S. as a dry powder formulation, and the molecule has twenty years of worldwide use. Perforomist Inhalation Solution is the first and only FDA-approved nebulized formoterol fumarate. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

"The first nebulized formoterol fumarate, Perforomist Inhalation Solution offers a new treatment option to COPD patients," said Nicholas J. Gross, MD, PhD, Principal Investigator of the Phase III pivotal clinical trial and an expert on lung diseases, particularly COPD. "By nebulizing with Perforomist Inhalation Solution twice a day once in the morning and once in the evening many COPD patients can achieve better control of their disease symptoms. The convenience of such simple dosing combined with a drug delivery option favored by many patients may provide improved symptom control and a better quality of life for the millions of Americans who live with COPD."

Mel Engle, President and CEO at DEY, noted, "As the US leader in nebulized respiratory products, we are thrilled to bring Perforomist Inhalation Solution, a new patented treatment option for COPD patients, to the market. Nebulization is a time tested and reliable drug delivery option. DEY has a long history of developing and marketing innovative respiratory therapeutics. The approval of Perforomist Inhalation Solution fits perfectly with our overall strategy for respiratory medications."

Gene L. Colice, MD, Department
'"/>

Contact: Harriet Ullman
harriet.ullman@fkhealth.com
617-761-6776
Feinstein Kean Healthcare
11-May-2007


Page: 1 2

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. VCR -- FDA approves home discharge for US patients
4. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
5. FDA approves Vectibix to treat patients with metastatic colorectal cancer
6. 5,000 rare diseases need drugs, but Europe only approves a handful each year
7. FDA approves room temperature storage of ZLB Behrings Helixate FS
8. FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference

Post Your Comments:
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
(Date:3/5/2015)... Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ) ... tort litigation currently underway in the Philadelphia Court ... hearing testimony in the proceeding’s second bellwether trial ... cause gynecomastia, or male breast growth. According to ... on behalf of a plaintiff who was prescribed ...
(Date:3/5/2015)... 2015 Rhode Island Medical Imaging (RIMI) was ... row to support the Providence College (PC) women’s basketball program’s ... purchase of the ‘Think Pink’ uniforms, which were worn during ... opponent DePaul University at Alumni Hall/Mullaney Gymnasium in Providence, R.I. ... of the PC women’s basketball’s ‘Pink Out’ event,” said Dr. ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 On March ... “Butt Augmentation, Labiaplasty on the Rise, Plastic Surgeons Say,” ... the American Society for Aesthetic Plastic Surgery ... Both groups reported a year-over-year doubling of surgical butt ... physicians quoted in the article, this increase can be ...
(Date:3/5/2015)... TCS Healthcare Technologies (TCS), a leading provider ... management arena, is pleased to announce a webinar focusing ... Care™ (ACUITY) version 7.20. The session will focus on ... of automation. , The webinar, scheduled for March 18, ... Jeff Frater, RN, BSN, Director of Partner Development at ...
Breaking Medicine News(10 mins):Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "India Pharma Outlook 2015: Accelerating growth to the next ... report to their offering. Domestic ... the 2013 caused by the market,s reaction to the ... to continue to be healthy, as the momentum continues ...
(Date:3/5/2015)... and HAMPTON, N.J. , March 5, ... MNK ), a leading global specialty biopharmaceutical company, ... today that they have entered into a definitive agreement ... Inc. from a Madison Dearborn -led investor group ... Subject to customary closing conditions, the parties ...
(Date:3/5/2015)... -- According to a new market research ... Disposables), by Type (Invasive, Minimally Invasive, Non-Invasive), by End-User ... - Analysis & Global Forecast to 2019" , the ... $1,107.4 Million by 2019 from $887.8 Million in 2014, ... 4.5% during the forecast period. Browse ...
Breaking Medicine Technology:India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
Cached News: